Share on

U.S. Transplant Diagnostics Market Research Report – Segmented By Technology, Product, Application, Type, End User and Country – Industry Size, Share, Trends, COVID-19 Impact and Growth Forecast (2023 to 2028)

Published: March, 2023
ID: 11549
Pages: 90
Formats: report pdf report excel report power bi report ppt

U.S. Transplant Diagnostics Market Size (2023 to 2028)

The size of the Transplant diagnostics market in the U.S. is forecasted to grow at a CAGR of 6.92% between 2023 to 2028 and will be worth USD  998 million by the end of 2028.

The growing number of transplantation procedures in the United States primarily drives the U.S. transplant diagnostics market. In 2021, an estimated 40,000 organ transplants were performed in the U.S., most of which were liver and kidney transplants. In addition, the incidence of liver and kidney failures is growing significantly in the United States due to the increasing adoption of sedentary lifestyles, including increasing consumption of alcohol, smoking, and unhealthy diet. As a result, patients undergoing transplantation procedures prefer to have transplant diagnostics before or after the transplantation as this diagnostic helps check if the donor organ is suitable for the receptor body.

The growing geriatric population in the U.S. and increasing organ rejection cases post-transplantation surgeries are anticipated to aid the transplant diagnostics market in the U.S. Organ rejection is the most prominent reason why adopting the transplant diagnostics procedure before or after the transplantation is vital. Therefore, most healthcare providers prefer to perform a transplant diagnostic before the transplantation procedure, ensuring a smooth surgery with minimal side effects.

The rising adoption of technological developments in transplantation diagnostics is further propelling the growth rate of the U.S transplant diagnostics market. Increasing focus of key market participants to develop effective medical devices that help identify the donor organ that is possibly set to the receptor body by taking a few samples from both candidates involved to reduce the chances of organ rejection after the transplanting process. Further, the growing investment by the U.S. government, favorable reimbursement policies, and increasing research and development activities are anticipated to fuel the growth rate of the U.S. transplant diagnostics market.

On the other hand, high costs associated with diagnostic procedures and medical equipment are one of the major factors restraining the growth of the U.S. transplant diagnostics market. In addition, the lack of skilled professionals, organ donors, and advanced infrastructure hamper the U.S. transplant diagnostics market growth.

This research report on the U.S. transplant diagnostics market has been segmented & sub-segmented into the following categories.

By Technology:

  • Molecular Assays
    • PCR-Based Molecular Assays
      • Real-Time PCR
      • Sequence-Specific Primer-PCR
      • Sequence-Specific Oligonucleotide-PCR
      • Other PCR-Based Molecular Assays
    • Sequencing-Based Molecular Assays
      • Sanger Sequencing
      • Next-Generation Sequencing
      • Other Sequencing Molecular Assays
  • Non-Molecular Assays

By Product:

  • Consumables
  • Instrument
  • Reagent
  • Software & Services

By Application:

  • Diagnostic Applications
    • Pre-Transplantation Diagnostics
      • Infectious Disease Testing
      • Histocompatibility Testing
      • Blood Profiling
    • Post-Transplantation Diagnostics
  • Research Applications

By Transplant Type:

  • Heart Transplant
  • Kidney Transplant
  • Liver Transplant
  • Stem Cell Transplant

By End-User:

  • Labs
  • Hospitals
  • Transplant Centres
  • Research Labs & Academic Institutes

By Country:

  • The United States

The U.S. transplant diagnostics market is estimated to account for a significant global market share during the forecast period. It is predicted to be a leading contributor to the North American market during the forecast period. The primary factors contributing to the growth of the U.S. market are the increased use of innovative procedures and medical instruments, increasing healthcare expenditure, and the availability of skilled professionals. Also, the presence of sophisticated healthcare infrastructure in the U.S. favors market growth. In addition, the U.S. market is predicted to be driven by the increasing adoption of personalized medicine, stem cell therapies, and soft tissue transplants to augment regional market growth. With the help of technological advancements, many transplant procedures are being performed by multi-specialty hospitals in developed markets. Growing funding opportunities provided by the U.S. government and private collaborations are expected to uplift market growth.

In addition, the increasing adoption of advanced treatment, ensuring the patient's safety & providing quality treatment, and increasing healthcare expenditure is expected to support the market growth. The U.S. government has taken several measures to accept novel treatments for the population in their country to reduce errors in healthcare systems. Furthermore, several clinical centers in the United States provide multiple options for better transplant diagnostics treatments, resulting in market growth.

KEY MARKET PARTICIPANTS:

CareDx, Pacific Biosciences of California, Illumina, Thermo Fischer Scientific, GenDx, and Immucor are some notable companies operating in the U.S. transplant diagnostics market.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample